Article ; Online: Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals.
European journal of drug metabolism and pharmacokinetics
2018 Volume 43, Issue 1, Page(s) 103–113
Abstract: Background and objectives: Maximum plasma concentration of biopharmaceuticals sometimes occurs long after completion of intravenous infusion. The objective of this research was to study the hypothetical adsorption of biopharmaceuticals to endothelium ... ...
Abstract | Background and objectives: Maximum plasma concentration of biopharmaceuticals sometimes occurs long after completion of intravenous infusion. The objective of this research was to study the hypothetical adsorption of biopharmaceuticals to endothelium and infusion material, which may theoretically explain this phenomenon. Methods: Infusion procedures were mimicked in an artificial vessel covered with a confluent monolayer of endothelial cells. Three monoclonal antibodies (MAbs) and C1 inhibitor were studied. Results: Adsorption of MAbs to endothelium was observed followed by release when the vessel was subsequently perfused with buffer. Adsorption to infusion material also occurred to various degrees and in a seemingly random fashion, with a loss of up to 15% during a single flush of the line, but release from the line was not seen. Conclusions: Our results indicate that adsorption of biopharmaceuticals to endothelium can occur. This observation can explain the increase in plasma concentration after completion of intravenous administration. |
---|---|
MeSH term(s) | Adsorption ; Antibodies, Monoclonal/pharmacokinetics ; Bevacizumab/pharmacokinetics ; Biopharmaceutics ; Cells, Cultured ; Complement C1 Inhibitor Protein/administration & dosage ; Complement C1 Inhibitor Protein/pharmacokinetics ; Endothelium/metabolism ; Humans ; Immunoglobulin G/administration & dosage ; Immunoglobulin G/metabolism ; Infusions, Intravenous ; Time Factors ; Trastuzumab/pharmacokinetics |
Chemical Substances | Antibodies, Monoclonal ; Complement C1 Inhibitor Protein ; Immunoglobulin G ; Bevacizumab (2S9ZZM9Q9V) ; Trastuzumab (P188ANX8CK) |
Language | English |
Publishing date | 2018-02 |
Publishing country | France |
Document type | Journal Article |
ZDB-ID | 196729-0 |
ISSN | 2107-0180 ; 0398-7639 ; 0378-7966 |
ISSN (online) | 2107-0180 |
ISSN | 0398-7639 ; 0378-7966 |
DOI | 10.1007/s13318-017-0430-1 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1236: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.